Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCTNASDAQ:AUPHNASDAQ:HRTXNASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$2.82+5.6%$2.41$1.05▼$4.13$264.81M1.89597,153 shs661,418 shsAUPHAurinia Pharmaceuticals$7.49+0.1%$8.08$5.20▼$10.67$1.01B1.161.37 million shs2.25 million shsHRTXHeron Therapeutics$2.15-0.9%$2.06$1.04▼$3.73$331.06M1.182.19 million shs2.49 million shsSUPNSupernus Pharmaceuticals$32.07+0.8%$32.25$25.55▼$40.28$1.78B0.7476,937 shs474,541 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+0.37%-5.43%-12.90%+99.26%-26.63%AUPHAurinia Pharmaceuticals-11.69%-7.08%-4.83%-8.67%+36.25%HRTXHeron Therapeutics+4.83%+0.93%+14.81%-2.69%-37.46%SUPNSupernus Pharmaceuticals+0.95%+0.47%+0.09%-3.05%+19.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.663 of 5 stars3.52.00.00.00.60.80.6AUPHAurinia Pharmaceuticals2.7257 of 5 stars3.51.00.00.02.60.81.9HRTXHeron Therapeutics3.9416 of 5 stars3.50.00.04.23.31.70.6SUPNSupernus Pharmaceuticals2.3105 of 5 stars2.22.00.04.11.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75174.82% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5053.54% UpsideHRTXHeron Therapeutics 3.00Buy$5.00132.56% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0012.25% UpsideCurrent Analyst Ratings BreakdownLatest HRTX, SUPN, ADCT, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.006/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/15/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.004/11/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M3.95N/AN/A($2.10) per share-1.34AUPHAurinia Pharmaceuticals$235.13M4.30$0.31 per share24.25$2.68 per share2.79HRTXHeron Therapeutics$144.29M2.27N/AN/A($0.22) per share-9.77SUPNSupernus Pharmaceuticals$661.82M2.71$4.20 per share7.63$18.76 per share1.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)AUPHAurinia Pharmaceuticals$5.75M$0.2826.7513.38N/A16.11%14.27%9.93%7/30/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1128.8922.27N/A9.27%12.23%9.17%8/5/2025 (Estimated)Latest HRTX, SUPN, ADCT, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ADCTADC Therapeutics-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.464.16AUPHAurinia Pharmaceuticals0.165.935.26HRTXHeron TherapeuticsN/A2.401.76SUPNSupernus PharmaceuticalsN/A2.442.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%AUPHAurinia Pharmaceuticals36.83%HRTXHeron Therapeutics80.01%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%AUPHAurinia Pharmaceuticals12.20%HRTXHeron Therapeutics5.86%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.18 million93.82 millionOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableHRTXHeron Therapeutics300152.56 million143.62 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableHRTX, SUPN, ADCT, and AUPH HeadlinesRecent News About These CompaniesSage Sacks Entire Staff After Supernus BuyoutJune 30 at 10:42 PM | biospace.comBSupernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 27, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five yearsJune 23, 2025 | uk.finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Hold Rating by Wall Street ZenJune 21, 2025 | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJune 18, 2025 | businesswire.comSupernus Pharma to Buy Sage Therapeutics for Up to $795 MillionJune 16, 2025 | marketwatch.comSupernus enters depression drug market with up to $795 million Sage dealJune 16, 2025 | msn.comSupernus to acquire depression drugmaker SageJune 16, 2025 | msn.comSupernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage TherapeuticsJune 16, 2025 | msn.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.June 16, 2025 | prnewswire.comSupernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M DealJune 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock newsJune 16, 2025 | gurufocus.comSage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.June 16, 2025 | barrons.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16, 2025 | gurufocus.comSupernus Pharma to acquire Sage Therapeutics in up to $795 million dealJune 16, 2025 | reuters.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product PortfolioJune 16, 2025 | globenewswire.comAzzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 16, 2025 | marketbeat.comGAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 16, 2025 | marketbeat.comWedge Capital Management L L P NC Acquires 13,955 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 10, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LPJune 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX, SUPN, ADCT, and AUPH Company DescriptionsADC Therapeutics NYSE:ADCT$2.82 +0.15 (+5.62%) Closing price 03:59 PM EasternExtended Trading$2.81 -0.01 (-0.39%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Aurinia Pharmaceuticals NASDAQ:AUPH$7.49 +0.01 (+0.13%) Closing price 04:00 PM EasternExtended Trading$7.56 +0.06 (+0.87%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Heron Therapeutics NASDAQ:HRTX$2.15 -0.02 (-0.92%) Closing price 04:00 PM EasternExtended Trading$2.20 +0.05 (+2.33%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Supernus Pharmaceuticals NASDAQ:SUPN$32.07 +0.25 (+0.79%) Closing price 04:00 PM EasternExtended Trading$33.35 +1.28 (+3.99%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.